Vik Adhopia

Vik Adhopia is a senior reporter with the Health Unit at CBC News. He joined CBC National Radio News in Toronto in 1995 and then began his coast-to-coast-to-coast journalistic odyssey, reporting from Iqaluit, Prince George, B.C., Vancouver, St. John's, N.L., and finally back to Toronto again.

Latest from Vik Adhopia

2 Canadian fertility supplements among those under fire from U.S. watchdog

The U.S. Center for Science in the Public Interest has called on regulators to take enforcement action against 27 companies — including two Canadian ones — that sell fertility supplements after its investigation found there's no scientific evidence the products help women get pregnant.

Why doctors need to walk a 'fine line' when talking to parents about alternative therapies for autism

Given that many parents of children with autism seek out complementary and alternative therapies, the Canadian Paediatric Society says it's important that doctors get informed and talk about them — especially since those therapies are often expensive, unproven and even potentially harmful.

After long-awaited recognition, serious research begins on chronic fatigue syndrome

A network of Canadian scientists is trying to make up for lost time in their search for a standard diagnostic test and treatment for myalgic encephalomyelitis/chronic fatigue syndrome. About 580,000 Canadians live with the disease, yet there has been little research into ME/CFS until recently.

Unnecessary vitamin B12 shots costing Ontario millions, study finds

A review of patient records published in the journal JAMA Internal Medicine has found 64 per cent of Ontario seniors who received vitamin B12 shots had no evidence of B12 deficiency. The unnecessary shots cost the provincial health-care system $45.6 million a year.
SECOND OPINION

Omega-3: The treatment in search of an illness makes a comeback

Researchers have renewed interest in omega-3 supplements despite years of research that shows they have little to no health benefit. The latest meta-analysis finds it could alleviate some of the symptoms of depression in adults.

Tips for surviving — and thriving during — school transitions

Experts in psychology and education share what makes students thrive during the difficult transition to a higher level of schooling.

'Brilliant': Artificial gravity isn't just science fiction

In what sounds like something straight out of science fiction, researchers are testing out a form of artificial gravity to counter the physiological hazards of weightlessness astronauts experience in space.
SECOND OPINION

Family doctors want term 'family medicine' protected legally

Family physicians are concerned that terminology associated with their profession — such as "family medicine" — could be misused by people who are not medical doctors, according to the results of an informal internal poll by the College of Family Physicians of Canada.
Second Opinion

Drug companies won't fix wasteful eye drops — so some students did

It's the time of year when people with allergies reach for their antihistamine eye drops to get some relief from itchiness and irritation. But much of that medicine ends up running down the cheeks in a waste of resources some students are working to change.
SECOND OPINION

Ontario's anti-smoking program Leave The Pack Behind left behind by government cuts

Leave The Pack Behind said it helped 40,000 people quit smoking in Ontario over its 19 years in operation. It's shutting down later this month after Ontario's Progressive Conservative government dropped its funding in its latest budget.
SECOND OPINION

Event billed as 'national pharmacare forum' dominated by groups opposed to universal drug plan

Canada's minister of health Ginette Petitpas Taylor faced criticism for being the keynote speaker at an event billed as a "national pharmacare forum" that was dominated by industries and groups that oppose a universal single-payer national drug plan.

Brain-injury device licensed by Health Canada was rejected by the FDA

The U.S. Food and Drug Administration's refusal to license a therapeutic device intended to help brain-injured people is raising questions about the rigour of Health Canada's approval process.
SECOND OPINION

The staggering cost of Type 1 diabetes: It's not just about insulin

Public insurance programs paid an average of $967 annually on insulin for people with Type 1 diabetes last year. That’s 33 per cent more than in 2011. But insulin is just a small portion of the staggering costs of managing the condition.
SECOND OPINION

Privacy: A hole in the virtual medicine cabinet

Researchers hoped health data would be treated as personal and sensitive. They were disappointed to find the sharing going on was really "business as usual."

There's no easy answer to the 'one issue per visit' problem

It's difficult to find any statistics on it, but Canadians have likely encountered the "one issue per visit" rule in a doctor's office or know of someone who has.